Panbela Therapeutics Book/Share
What is the Book/Share of Panbela Therapeutics?
The Book/Share of Panbela Therapeutics Inc. is -2.70
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on NASDAQ compared to Panbela Therapeutics
What does Panbela Therapeutics do?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Companies with book/share similar to Panbela Therapeutics
- SAExploration has Book/Share of -2.80
- La Perla Fashion N.V has Book/Share of -2.78
- Medigard has Book/Share of -2.78
- Melstar Information Technologies has Book/Share of -2.76
- Avid Technology has Book/Share of -2.75
- AIFarm has Book/Share of -2.73
- Panbela Therapeutics has Book/Share of -2.70
- Cidara Therapeutics Inc has Book/Share of -2.66
- Pressure BioSciences has Book/Share of -2.65
- Prakash Steelage has Book/Share of -2.63
- Elio Motors has Book/Share of -2.62
- JB&ZJMY Co has Book/Share of -2.60
- Pressure BioSciences has Book/Share of -2.59